|
Health Condition(s) or Problem
|
Coronary Artery Disease
|
|
Lay Summary
|
The main purpose of this study is to compare myocardial perfusion imaging using Rubidium-82
PET with Tc-99m-MIBI SPET, in the evaluation of significant Coronary Artery Disease (CAD).
(from ClinicalTrials.gov)
|
|
Who can enter the trial
|
Inclusion Criteria:
- Referred for scintigraphy to assess myocardial ischaemia
- Ability to give informed written consent.
Exclusion Criteria:
- Impaired capacity to consent
- Pregnancy, or breastfeeding
- Allergy to iv contrast
- Renal failure
- Severe Uncontrolled asthma
- Claustrophobia
|
|
Who cannot enter the trial
|
Inclusion Criteria:
- Referred for scintigraphy to assess myocardial ischaemia
- Ability to give informed written consent.
Exclusion Criteria:
- Impaired capacity to consent
- Pregnancy, or breastfeeding
- Allergy to iv contrast
- Renal failure
- Severe Uncontrolled asthma
- Claustrophobia
|
|
What will happen
|
Drug; Rubidium-82; Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use; Single arm; CardioGen-82; Drug; Sestamibi. reconstitution with sodium pertechnetate (99mTc); Maximum dose allowed per injection: 1000 MBq Intravenous Use; Single arm; Technescan MIBI
|
|
Primary aim
|
The specificity of detecting significant coronary artery disease (as defined as being >70% stenosis, on coronary CT angiography)
|
|
Secondary Aim
|
Evaluate any difference in the clinical interpretation of the Rubidium-82 PET and Tc-99m-MIBI SPET images.; Up to 2 days; No; Evaluate any difference in "Percentage myocardium" that is hypoperfused, between Rubidium-82 PET and Tc-99m-MIBI SPET.; Up to 2 days; No; Evaluate any difference in image quality, artefacts and interpretative confidence between Rubidium-82 PET and Tc-99m-MIBI SPET.; Up to 2 days; No; Evaluate any adverse events or reactions, during Rubidum-82 or Tc-MIBI administration.; Up to 2 days; Yes
|
|
Participant Information Sheet
|
Sorry, not currently available
|
|
Website
|
Sorry, not currently available
|
|
Recruitment Status
|
Recruiting
|
|
Nation
|
England
|
|
Location
|
London
|